Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States

Generic entry of newer anticoagulants is expected to decrease the costs of atrial fibrillation management. However, when making switches between brand and generic medications, bioequivalence concerns are possible. The objectives of this study were to predict and compare the lifetime cost‐effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ching‐Yu, Pham, Phuong N., Kim, Sarah, Lingineni, Karthik, Schmidt, Stephan, Diaby, Vakaramoko, Brown, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070788/
https://www.ncbi.nlm.nih.gov/pubmed/32053288
http://dx.doi.org/10.1111/cts.12719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070788/
https://www.ncbi.nlm.nih.gov/pubmed/32053288
http://dx.doi.org/10.1111/cts.12719

Ejemplares similares